As of August 31, 2026, Rapid Dose Therapeutics Corp carries a market capitalization of 11.75M, placing it among publicly traded companies globally. Its enterprise value stands at 15.82M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 11.75M |
| Enterprise Value | 15.82M |
As of August 31, 2026, Rapid Dose Therapeutics Corp has 137.78M shares outstanding.
| Shares Outstanding | 137.78M |
These figures are as of August 31, 2026. The price-to-sales ratio is 7.52, and the price-to-book ratio stands at -1.99.
| PS Ratio | 7.52 |
| PB Ratio | -1.99 |
| P/TBV Ratio | -1.99 |
| P/FCF Ratio | 5.47 |
| P/OCF Ratio | 43.51 |
These figures are as of August 31, 2026. The EV/Sales ratio of 10.35 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 15.82M versus a market cap of 11.75M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 10.35 |
As of August 31, 2026, Rapid Dose Therapeutics Corp maintains a current ratio of 0.03, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -68.89, indicating conservative leverage, while an interest coverage ratio of -1.10 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.03 |
| Quick Ratio | 0.02 |
| Debt / Equity | -68.89 |
| Debt / EBITDA | -4.06 |
| Interest Coverage | -1.10 |
These figures cover the twelve months ended August 31, 2026. Return on assets (ROA) is negative at -87.55, reflecting losses generated across the asset base. Inventory turnover of 7.97 indicates how many times Rapid Dose Therapeutics Corp sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | -87.55 |
| Inventory Turnover | 7.97 |
As of the close on November 9, 2026, Rapid Dose Therapeutics Corp's stock has declined approximately 61.87% over the past 52 weeks. The 50-day moving average sits at 0.08, while the 200-day moving average is 0.22.
| 52-Week Price Change | -61.87% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.22 |
Over the twelve months ended August 31, 2026, Rapid Dose Therapeutics Corp generated 1.53M in revenue and converted that into -2.27M in net income, yielding earnings per share of -0.02. EBITDA reached -1.00M, while operating income came in at -1.35M.
| Revenue | 1.53M |
| Gross Profit | 751,147.21 |
| Operating Income | -1.35M |
| Pretax Income | -2.27M |
| Net Income | -2.27M |
| EBITDA | -1.00M |
| EBIT | -1.35M |
| Earnings Per Share (EPS) | -0.02 |
As of August 31, 2026, Rapid Dose Therapeutics Corp holds 6,225.05 in cash and equivalents against 4.08M in total debt, resulting in a net debt position of 2.53M. Total book value stands at -5.92M, with working capital of -6.50M providing operational flexibility.
| Cash & Cash Equivalents | 6,225.05 |
| Total Debt | 4.08M |
| Net Debt | 2.53M |
| Equity (Book Value) | -5.92M |
| Book Value Per Share | -0.04 |
| Working Capital | -6.50M |
Rapid Dose Therapeutics Corp produced 264,238.96 in operating cash flow over the twelve months ended August 31, 2026. After subtracting 1.84M in capital expenditures, free cash flow totaled 2.10M - equivalent to 0.02 per share.
| Operating Cash Flow | 264,238.96 |
| Capital Expenditures | 1.84M |
| Free Cash Flow | 2.10M |
| FCF Per Share | 0.02 |
Over the twelve months ended August 31, 2026, Rapid Dose Therapeutics Corp posted a gross margin of 49.12, reflecting its pricing power and cost economics. The operating margin of -88.50 and net profit margin of -148.27 provide insight into operational efficiency.
| Gross Margin | 49.12 |
| Operating Margin | -88.50 |
| Pretax Margin | -148.27 |
| Profit Margin | -148.27 |
| EBITDA Margin | -65.67 |
These figures cover the twelve months ended August 31, 2026. Free cash flow yield stands at 18.29, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 18.29, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Rapid Dose Therapeutics Corp shareholders.
| Shareholder Yield | 18.29 |
| FCF Yield | 18.29 |
As of August 31, 2026, Rapid Dose Therapeutics Corp has an Altman Z-Score of -27.77, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -27.77 |
Already premium?